Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.33 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.32 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18587983 | 0.85 | — | — | |
| SCHEMBL2694843 | 0.83 | HRH3 (0.33) | CHRM2CHRM4CHRM1HRH3L3MBTL3 | |
| SCHEMBL735844 | 0.80 | — | — | |
| SCHEMBL3722977 | 0.78 | CHRM2 (0.40) | CHRM2CHRM4CHRM1HRH3L3MBTL3 | |
| SCHEMBL2695536 | 0.77 | SMN1; SMN2 (0.41) | CHRM2CHRM4CHRM1HRH3L3MBTL3 | |
| SCHEMBL737400 | 0.75 | — | — | |
| SCHEMBL735797 | 0.75 | — | — | |
| SCHEMBL14862483 | 0.72 | SMN1; SMN2 (0.50) | CHRM2CHRM4CHRM1HRH3L3MBTL3 | |
| SCHEMBL4053971 | 0.72 | — | — | |
| SCHEMBL736825 | 0.72 | SLC18A3 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031676-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-01-31 | — | — | US | claimed |
| EP-3341378-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2018-07-04 | — | — | EP | claimed |
| WO-2017036968-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-09 | — | — | WO | claimed |
| US-20190031676-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-01-31 | — | — | US | disclosed |
| EP-3341378-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017036968-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2017-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031676-A1 | ANTIBACTERIAL ANNULATED PYRROLIDIN-2-ONE DERIVATIVES | PYCR1, PSPH, RPSA | CHRM2 2049/4885CHRM4 2638/4885CHRM1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.